High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion
| Autor: | Madeleine C. Killer, Elisabeth Mack, Nina Timmesfeld, Roland Moll, Andreas Neubauer, Anja Lorch, Melina Schmitt, Michael Lohoff, Jörg Beyer, Cornelia Brendel, Verena Nilius, Andreas Burchert |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
0301 basic medicine Oncology medicine.medical_specialty B4GALT1 medicine.medical_treatment Immunology 610 Medicine & health immunosurveillance Lower risk lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Immunology and Allergy Cytotoxic T cell Testicular cancer T-lymphocytes Cisplatin Chemotherapy business.industry Brief Report Hazard ratio lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Interleukin 10 030104 developmental biology Cytokine 030220 oncology & carcinogenesis biomarker germ-cell cancer lcsh:RC581-607 business medicine.drug |
| Zdroj: | Oncoimmunology OncoImmunology, Vol 7, Iss 5 (2018) Nilius, Verena; Killer, Madeleine C; Timmesfeld, Nina; Schmitt, Melina; Moll, Roland; Lorch, Anja; Beyer, Jörg; Mack, Elisabeth; Lohoff, Michael; Burchert, Andreas; Neubauer, Andreas; Brendel, Cornelia (2018). High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion. Oncoimmunology, 7(5), e1423169. Taylor & Francis 10.1080/2162402X.2017.1423169 |
| ISSN: | 2162-402X 2162-4011 |
| DOI: | 10.1080/2162402X.2017.1423169 |
| Popis: | Survival of patients with germ-cell cancer (GCC) and primary progression or relapse after cisplatin-based first-line chemotherapy is highly heterogeneous, ranging from close to zero to more than 70%. We investigated β-1,4-Galactosyltransferase-I (B4GALT1) expression levels in peripheral lymphocytes in a cohort of 46 testicular cancer patients. B4GALT1 enhances immune cell crosstalk via glycosylation of surface molecules. A high expression level of B4GALT1 in T-lymphocytes, but not in monocytes, was associated with a lower risk of relapse with a hazard ratio (HR) of 0.66 (95% confidence interval (CI) of HR: 0.45-0.97; p = 0.02) upon multivariate Cox regression analysis. Correspondingly, interleukin 10 (IL10), a cytokine released by cytotoxic T-cells, was likewise significantly elevated in T-lymphocytes of non-relapse GCC patients (HR: 0.3; 95% CI of HR: 0.14-0.65; p = 0.002). Our data indicate that glycosylation and activation of T-lymphocytes may play a pivotal role in disease control in GCC patients with primary progressive or relapsed disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|